Urethra-Sparing Prostate Cancer Stereotactic Body Radiation Therapy: Sexual Function and Radiation Dose to the Penile Bulb, the Crura, and the Internal Pudendal Arteries From a Randomized Phase 2 Trial-Reference-Cited by-同舟云学术

Urethra-Sparing Prostate Cancer Stereotactic Body Radiation Therapy: Sexual Function and Radiation Dose to the Penile Bulb, the Crura, and the Internal Pudendal Arteries From a Randomized Phase 2 Trial

Published:2023-12 Issue: Volume: Page:
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Achard Vérane^ORCID,Zilli Thomas,Lamanna Giorgio,Jorcano Sandra,Bral Samuel,Rubio Carmen,Oliveira Angelo,Bottero Marta,Bruynzeel Anna M E,Ibrahimov Roman,Minn Heikki,Symon Zvi,Constantin Guillaume,Miralbell Raymond

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference41 articles.

1. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer;Hamdy;N Engl J Med,2023

2. Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study);Lane;BJU Int,2022

3. Radiotherapy for prostate cancer and sexual health;Incrocci;Transl Androl Urol,2015

4. Quality of life and satisfaction with outcome among prostate-cancer survivors;Sanda;N Engl J Med,2008

5. Quality of life three years after diagnosis of localised prostate cancer: Population based cohort study;Smith;BMJ,2009

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acute Toxicity and Early Prostate Specific Antigen Response After Two-Fraction Stereotactic Radiation Therapy for Localized Prostate Cancer Using Peri-Rectal Spacing – Initial Report of the SABR-Dual Trial;International Journal of Radiation Oncology*Biology*Physics;2024-07

2. SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer;BMC Cancer;2024-04-08